Send us a text

On this episode of IPWatchdog Unleashed, Gene Quinn sits down with one of the leading PTAB practitioners and strategist Scott McKeown to unpack the USPTO’s controversial “one-and-done” PTAB rule package. With more than 10,000 comments filed and over 700 individual commenters weighing in, the proposal has become a flashpoint for questions that go way beyond discretionary denial and AIA trials.

Gene and Scott drill down on what USPTO Director John Squires is actually trying to accomplish, why the Office is now wrapping aggressive policy changes in “fairness” rhetoric, why some view this proposed rules package to be an effort at de facto legislation, and why former Members of Congress who wrote the AIA are now publicly objecting to the rules package. They also flag the real-world impact on small and mid-size companies, the growing risk that the PREVAIL Act and PERA will now be dead on arrival, and what this latest PTAB fight tells us about a broken Congress, an overactive administrative state, and a patent system that simply can’t deliver quiet title.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

Join Gene Quinn and John White in this episode of IPWatchdog Unleashed as they delve into the intricacies of passing the Patent Bar and its latest updates. With over two decades of friendship and collaboration in the patent industry, Gene and John share personal anecdotes, discuss the shifting phases of the patent exam, and scrutinize the impact of artificial intelligence on the exam and exam preparation. They then pivot for the second half of the conversation to more broadly discuss AI and how it is being used, and perhaps how it should be used, in patent practice. They also explore the importance of staying current with legal changes, the shortcomings of relying on AI for legal accuracy, and provide valuable insights for both veteran practitioners and newcomers to the field. Tune in for an enriching conversation that combines professional expertise, personal experiences and that singular brand of humor Gene and John bring to the topic. 

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

This week on IPWatchdog Unleashed, we panel discussion that took place on October 27 as a part of our annual life sciences program. Initially styled as a conversation about how artificial intelligence is transforming life sciences, it becomes quickly apparent that the conversation was not going to be limited to the life sciences sector but instead was a robust discussion about what any innovative company should consider when considering the adoption of AI tools. Indeed, the discuss was really about what all companies must do to allow or even encourage the use of AI by researchers and scientists without opening catastrophic IP and data-security failures, risk and liability. We address data protection, trade secret risks, employee monitoring, AI governance, the importance of using AI responsibly, and much more.

Moderated by Gene Quinn, founder of IPWatchdog, the conversation brought together Brian Cocca, Executive Director & Assistant General Counsel for IP at Regeneron; Gary Lobel, Chief IP Counsel; Drhuv Sud, Senior Director & Assistant General Counsel at Regeneron; and Giulia Toti, co-founder of Anchor AI. Collectively, the panel unpacked the real-world collision between AI adoption, IP protection, data governance, competitive strategy and risk.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

Every life-saving drug we know of—every cancer therapy, every vaccine, every breakthrough—started as an impossible idea. Turning that idea into reality takes more than science. It takes persistence, investment, and a patent system strong enough to protect innovation. In this episode of IPWatchdog Unleashed, Gene Quinn (IPWatchdog) sits down with Rob Sahr, a Shareholder at Wolf Greenfield, to unpack the extraordinary journey from molecule to medicine. Together, they explore how scientific breakthroughs depend not only on research and capital, but also on a stable and predictable patent system. From double patenting and government funding to judicial uncertainty and policy headwinds, the conversation dives into the fragile balance between innovation and access—and the miracles required to bring new drugs to life.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

In our latest IPWatchdog Unleashed podcast, we had a riveting and sometimes emotional conversation unfolded around one of the most pressing issues in life sciences today: the journey of life-saving drugs from laboratory to patient. We discuss the pivotal role a strong patent system plays in this important journey with guest Sherry Knowles. Sherry is the founder of Knowles Intellectual Property Strategies and former Chief Patent Counsel for GlaxoSmithKline. In addition to being one of the leading voices in the life sciences and patent industries, Sherry is also a cancer survivor. Among other things we discuss numerous patent system challenges facing innovator drug companies, the downward pressure generic drugs place on the industry and leading to important drugs becoming unavailable, the role of Pharmacy Benefit Mangers (PBMs) with respect to significantly raising the cost of drugs for Americans, and policy influences and legislation on Capitol Hill. Sherry also shares her personal story and insights into why patents are more than just legal constructs—they are deeply personal lifelines. 

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

This week on IPWatchdog Unleashed we have an interesting and entertaining conversation between Gene Quinn, President & CEO of IPWatchdog, Inc., and Henry Hadad, Chief IP Counsel and Deputy General Counsel at Bristol Myers Squibb. The conversation is wide ranging. They discuss the complexities and challenges patent laws are creating for medical diagnostics and cancer treatment. Henry shares his journey from law school to becoming a key player in the biopharmaceutical industry and elaborates on groundbreaking innovations in immuno-oncology that have transformed cancer treatment. The conversation delves into the impact of legislative and judicial changes on the IP landscape, the critical role of diagnostics in healthcare, and the importance of incentivizing innovation through a robust patent system. The episode concludes with reflections on the human impact of scientific advancements and the ongoing efforts required to find a cure for cancer. Henry’s final comment is one of optimism for innovators and the patent industry. 

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

This week on IPWatchdog Unleashed we will talk about trade disputes, regulatory overhauls, and sudden shifts in geopolitics and what all of that means for the business landscape and patent strategy.  

The changing business climate is requiring companies of all sizes to reevaluate strategy, and those that best navigate the transition will future-proof their companies and innovation pipelines, wind up stronger in the long run, and have a more diversified and stable trajectory. 

We will discuss building an IP strategy during turbulent times. To accomplish this we discuss tariffs and how many businesses are responding to tariffs, including efforts to move manufacturing to lower tariff countries, and what IP professionals need to have in mind as they find themselves with patent portfolios built for the business landscape and geography of the past, and with a strategy and portfolio that might not be optimal—or worse a strategy and portfolio that could be all wrong given how manufacturing centers, supply chains and global business realities are rapidly evolving.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

In this episode of IPWatchdog Unleashed, host Gene Quinn sits down with Gina Johnson, the Chief Legal Officer of Ridge Wallet, LLC. They dive into Ridge Wallet's approach to intellectual property, and how the company relies on design patents, utility patents, and trademarks to fully protect their products against fakes, dupes, counterfeits and knockoffs. Gina shares her transition from outside counsel to an in-house role, the strategic importance of IP in combating market confusion, and the challenges of dealing with knockoffs and counterfeits on platforms like Amazon and Alibaba. Key topics include the significance of foundational patents, design patents covering product silhouettes, the process of using so-called Schedule A cases for IP enforcement against copycat companies without any (or many) assets reachable in the United States, and the nuances of working within the “Amazon court” to police IP disputes outside of the federal court system. Gina also offers practical advice for startups on the value of early IP protection, and why robust IP protection should be a priority for startups and entrepreneurs.

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

In this special edition of the IPWatchdog Unleashed, Gene Quinn and his German counterparts discuss a recent major development at the Unified Patent Court (UPC) relating to Standard Essential Patents (SEPs) and injunctions. Featuring industry experts Dr. Tobias Wuttke, Arie Tol, and Dr. Tilman Müller, the conversation dives into the background of the case that lead to the first, final, permanent injunction being awarded in a standard essential patent (SEP) case at the UPC. We discuss the landmark ruling in Philips v. Belkin, which solidified the UPC's stance on providing permanent injunctions to victorious patent owners. The panel explores potential implications for patent owners, how the FRAND negotiation process is and was handled, geographical jurisdiction issues, and the benefits and risks associated with litigating in the UPC. 

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Send us a text

In this episode of IPWatchdog Unleashed, Gene Quinn and Dana Colarulli delve into the intricate world of patent policy and politics, discussing laws, the dynamic environment at the U.S. Patent and Trademark Office (USPTO). Dana, a partner at ACG Advocacy and the Executive Director of LES International (LESI), shares his extensive experience, from his time at the USPTO to his insights on high-growth technology businesses. They address critical topics such as the recent shake-ups at the USPTO, the controversial 'patent tax' proposal, the role of government in fostering innovation, how despite the fact that the USPTO is user-fee funded it is being swept up in broader Trump Administration efforts to downsize the federal government, what the word "innovation" really means, how businesses use intellectual property assets, the importance of predictable IP assets, the challenges of effective patent valuation, international collaboration and education to support small and medium size enterprises (SMEs), and much more. Join Gene and Dana for an in-depth look at the current state and future of patents, innovation, and what is happening inside the beltway. 

Visit us online at IPWatchdog.com.

You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.